Gilead to buy Immunomedics for $21bn
The move adds Trodelvy, a first-in-class antibody-drug conjugate approved to treat triple-negative breast cancer, to the drugmaker’s portfolio
Read More
Tag: Immunomedics
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
